Literature DB >> 2906529

The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis.

A Plaitakis1, E Constantakakis, J Smith.   

Abstract

Because recent studies showed a systemic defect in glutamate metabolism in amyotrophic lateral sclerosis (ALS), we measured the levels of free amino acids in frontal and cerebellar cortex and two areas of spinal cord obtained at autopsy from 22 patients who died of this disease. Glutamate levels were significantly decreased (by 21 to 40% of control values) in all areas investigated; cervical and lumbar spinal cord showed the greatest change. Aspartate levels were also significantly reduced (by 32 to 35%) in the spinal cord only. A positive correlation was shown between the changes of glutamate and aspartate as well as a significant alteration in the glutamate to glutamine ratio in the spinal cord of patients with ALS. Although we cannot exclude the possibility that these abnormalities may partly result from neuronal cell loss, the data suggest the presence of a generalized defect that may affect the neurotransmitter and metabolic pool of glutamate. The defect may be expressed more severely in the spinal cord than in other central nervous system areas. These results, taken together with the previously shown systemic abnormality, raise the possibility that distribution of glutamate between the intracellular and extracellular pool may be altered in ALS and may mediate the neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2906529     DOI: 10.1002/ana.410240314

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  32 in total

Review 1.  Treatment of amyotrophic lateral sclerosis.

Authors:  A Eisen; M Weber
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

2.  A double-blind placebo-controlled trial of L-threonine in amyotrophic lateral sclerosis.

Authors:  O Blin; J Pouget; G Aubrespy; C Guelton; A Crevat; G Serratrice
Journal:  J Neurol       Date:  1992-02       Impact factor: 4.849

3.  Neurotoxic acylpolyamines from spider venoms.

Authors:  K D McCormick; J Meinwald
Journal:  J Chem Ecol       Date:  1993-10       Impact factor: 2.626

4.  Evolution of the neurochemical profiles in the G93A-SOD1 mouse model of amyotrophic lateral sclerosis.

Authors:  Hongxia Lei; Elisabeth Dirren; Carole Poitry-Yamate; Bernard L Schneider; Rolf Gruetter; Patrick Aebischer
Journal:  J Cereb Blood Flow Metab       Date:  2018-02-05       Impact factor: 6.200

5.  Physiology of the fasciculation potentials in amyotrophic lateral sclerosis: which motor units fasciculate?

Authors:  Mamede de Carvalho; Michael Swash
Journal:  J Physiol Sci       Date:  2016-09-16       Impact factor: 2.781

6.  Effects of Branched-Chain Amino Acid Supplementation on Spontaneous Seizures and Neuronal Viability in a Model of Mesial Temporal Lobe Epilepsy.

Authors:  Shaun E Gruenbaum; Roni Dhaher; Amedeo Rapuano; Hitten P Zaveri; Amber Tang; Nihal de Lanerolle; Tore Eid
Journal:  J Neurosurg Anesthesiol       Date:  2019-04       Impact factor: 3.956

7.  Permeabilization of brain tissue in situ enables multiregion analysis of mitochondrial function in a single mouse brain.

Authors:  Eric A F Herbst; Graham P Holloway
Journal:  J Physiol       Date:  2015-01-23       Impact factor: 5.182

8.  Metabolomics profiling reveals profound metabolic impairments in mice and patients with Sandhoff disease.

Authors:  Li Ou; Michael J Przybilla; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2018-09-14       Impact factor: 4.797

9.  Fragmentation of the Golgi apparatus of motor neurons in amyotrophic lateral sclerosis revealed by organelle-specific antibodies.

Authors:  Z Mourelatos; H Adler; A Hirano; H Donnenfeld; J O Gonatas; N K Gonatas
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

10.  Neuronal glucose metabolism is impaired while astrocytic TCA cycling is unaffected at symptomatic stages in the hSOD1G93A mouse model of amyotrophic lateral sclerosis.

Authors:  Tesfaye W Tefera; Karin Borges
Journal:  J Cereb Blood Flow Metab       Date:  2018-03-19       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.